Tuesday, August 25, 2009
S & P 400 / Mid Cap Index
Some long term charts of this index. Next resistance: 50% fibonacci retracement.
OIL vs GAS
Following a suggestion of a good friend, here we can see the OIL / NATURAL GAS ratio.
It interesting to notice the bearish divergences in this ratio (full stochastics), and therefore, we can expect a possible rebound in the index. This mean that, in the near future, the probability of Natural Gas outperforming OIL is very high.
In addition, I suggest to look the long term situation of the Natural gas (here), which is struggling with a support @ USD 2.71.
Time for a reversal in Natural Gas? A big drop coming in Oil?. As it always happen, time will tell.
It interesting to notice the bearish divergences in this ratio (full stochastics), and therefore, we can expect a possible rebound in the index. This mean that, in the near future, the probability of Natural Gas outperforming OIL is very high.
In addition, I suggest to look the long term situation of the Natural gas (here), which is struggling with a support @ USD 2.71.
Time for a reversal in Natural Gas? A big drop coming in Oil?. As it always happen, time will tell.
Monday, August 24, 2009
Natural Gas: shelter?
Some long term charts on the Natural Gas Future. Time of rebound?
Natural Gas Future Weekly chart:
Natural Gas Future daily chart:
Natural Gas Future daily chart (only price)
Natural Gas Future monthly chart:
Natural Gas Future Long Term weekly chart:
Thursday, August 20, 2009
Exact Fibonacci's confluence at DOW JONES
We have a double confluence fibonacci's resistance in the DOW (both monthly and weekly charts).
Look at the 38.2% Fibonacci's resistance in the monthly chart (9.410 points), 20 years period, from 1989 to 2009.
Then, look the the 38.2% Fibonacci's resistance in the weekly chart (9.409 points, this chart is from the August 10 week), October 2007, September 2009. Link to the previous post (some additional charts)
Both coincides in the 9.410 level.
If we look at the technicals indicators, we can expect that the rally resumes, since they are very bullish, on both, weekly and monthly charts. But it will not be easy to overcome. Tight your stops!
Look at the 38.2% Fibonacci's resistance in the monthly chart (9.410 points), 20 years period, from 1989 to 2009.
Then, look the the 38.2% Fibonacci's resistance in the weekly chart (9.409 points, this chart is from the August 10 week), October 2007, September 2009. Link to the previous post (some additional charts)
Both coincides in the 9.410 level.
If we look at the technicals indicators, we can expect that the rally resumes, since they are very bullish, on both, weekly and monthly charts. But it will not be easy to overcome. Tight your stops!
Wednesday, August 19, 2009
Merck & Co. (MRK) Update
I find very interesting the pattern that MRK is developing, as the MRK fundamentals.
From the fundamentals:
Merck & Co. is one of the largest pharmaceutical companies in the world with 2008 annual sales of $24.2 billion. While Merck produces a wide assortment of medications, a few blockbuster drugs bring in the bulk of its revenue. Currently Merck's four most profitable drugs account for more than half of total sales.
The company's decision to acquire rival Schering-Plough (SGP) will be a major expansion, though, as the two companies' combined 2008 revenues were $47 billion.
Revenue, Net Income and Net Margin:
Interest coverage:
You can read more from:
http://www.wikinvest.com/wiki/Mrk
Technical perspective:
MRK Monthly chart:
Daily Chart:
Be careful, tight your stops if you are holding MRK, because it is developing some divergences (RSI, CMF, Accum/Dist, MACD and Force Index).
From the fundamentals:
Merck & Co. is one of the largest pharmaceutical companies in the world with 2008 annual sales of $24.2 billion. While Merck produces a wide assortment of medications, a few blockbuster drugs bring in the bulk of its revenue. Currently Merck's four most profitable drugs account for more than half of total sales.
The company's decision to acquire rival Schering-Plough (SGP) will be a major expansion, though, as the two companies' combined 2008 revenues were $47 billion.
Some key ratios:
Number of drugs in face I:Revenue, Net Income and Net Margin:
Interest coverage:
You can read more from:
http://www.wikinvest.com/wiki/Mrk
Technical perspective:
MRK Monthly chart:
Daily Chart:
Be careful, tight your stops if you are holding MRK, because it is developing some divergences (RSI, CMF, Accum/Dist, MACD and Force Index).
Subscribe to:
Posts (Atom)
